uniQure

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

In June, I presented hedges for uniQure shareholders looking to stay long while limiting their downside risk.

Crash Protection Kicks In For uniQure

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept.  05, 2019  (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs today announced the pricing of its underwritten public offering of 4,891,305 of its ordinary shares at a public offering price of $46.00 per share. The gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by uniQure, are expected to be approximately $225 million. All ordinary shares to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 733,695 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about September 10, 2019, subject to the satisfaction of customary closing conditions.

uniQure Announces Pricing of its Public Offering

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept.  04, 2019  (GLOBE NEWSWIRE) --  uniQure  N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has commenced an underwritten public offering of $200 million of its ordinary shares. All ordinary shares to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to $30 million of additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

uniQure Announces Proposed Public Offering

Pivotal Software

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept.  03, 2019  (GLOBE NEWSWIRE) --  uniQure N.V.  (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of  etranacogene dezaparvovec (AMT-061  ), an investigational  AAV5 -based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. Due to the high level of interest in the study from both patients and study investigators, uniQure expects to over-enroll up to six additional patients before the end of September.  Etranacogene dezaparvovec has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicines (PRIME) regulatory initiative by the European Medicines Agency.

uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug.  20, 2019  (GLOBE NEWSWIRE) --  uniQure  N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the promotions of  Sander van Deventer , M.D., Ph.D., to Executive Vice President, Research and Product Development, and  Alex Kuta , Ph.D., to Executive Vice President, Operations, effective immediately.  As a result of these changes, the Company is eliminating the Chief Operating Officer role, and Scott McMillan, Ph.D., will be retiring from uniQure.

uniQure Announces Leadership Promotions and Executive Transition

Morgan Stanley

Netflix

OrganiGram Holdings Inc.

The RealReal

Stitch Fix

Syndax Pharmaceuticals

As stocks keep pushing to highs again and again, where can you find smart stocks to buy right now? Check out these 7 excellent options.

7 Stocks to Buy With Over 20% Upside From Current Levels

CEO, CFO, Managing Director of Uniqure Nv (30-Year Financial, Insider Trades) Matthew C Kapusta (insider trades) sold 8,000 shares of QURE on 07/17/2019 at an average price of $71.45 a share.

Uniqure Nv (QURE) CEO, CFO, Managing Director Matthew C Kapusta Sold $571,600 of Shares

Steady progress with experimental gene therapies gave investors reasons to cheer.

What Drove uniQure 171% Higher in the First Half of 2019

Adverum Biotechnologies

Voyager Therapeutics

Good news has a way of attracting suitors.

3 Biotechs That Have Doubled This Year (Acquisition Next?)

Blueprint Medicines

Incyte

Verastem

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

Spark Therapeutics

Roche Holding AG

Gene therapy player Uniqure could head to the auction block, an analyst said Monday as shares of the biotech company popped. He also said Roche's plan to buy Spark Therapeutics could falter.

Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst

uniQure NV (NASDAQ: QURE) shares are trading higher by 6% in Monday's pre-market session following a Bloomberg report the company is exploring strategic options, including a potential sale.

Report: uniQure Could Put Itself Up For Sale

Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in uniQure (QURE) Stock?

Advanced Micro Devices

Kirkland Lake Gold

Snap

These four stocks in the high-momentum technology, biotech and mining areas are on the move.

4 Momentum Stocks to Watch: AMD, KL QURE & SNAP

AMD and 3 more momentum stocks to watch

uniQure (QURE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

uniQure (QURE) Jumps: Stock Rises 8.9%

CRISPR Therapeutics

Biotech stocks targeting gene therapy are going to be huge. Here are 3 gene therapy stocks to buy that have a ton of potential.

3 Top Gene Therapy Stocks That Could Soar

UniQure stock approached a breakout Friday after its experimental gene therapy showed improving promise in hemophilia B treatment. Shares are consolidating with a buy point at 69.70.

This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study

REGENXBIO

Solid Biosciences

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

4 Gene Therapy Players Likely to Become Buyout Targets in 2019

News for uniQure Stock (QURE)